

(This document is an English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)



August 26, 2026

Company name:	Hodogaya Chemical Co., Ltd.
Name of representative:	Yuto Matsumoto, President and Representative Director (Securities code: 4112, Prime Market of Tokyo Stock Exchange)
Inquiries:	Hideaki Hashizume, Executive Officer & General Manager Corporate Planning Department (Telephone: +81-3-6852-0327)

(Progress of Disclosure Matters) Notice Regarding Completion of Acquisition of Equity Interests (Making a Wholly Owned Subsidiary) of Framochem Francia-Magyar Finomkemiai Kft (Hungary)

As previously announced in the release titled “Notice Regarding Acquisition of Equity Interests (Making a Wholly Owned Subsidiary) of Framochem Francia-Magyar Finomkemiai Kft (Hungary)” dated March 27, 2026, Hodogaya Chemical Co., Ltd. (the "Company" or “HCC”) had entered into a Quota Purchase Agreement with the objective of acquiring 100% of the equity interests in Framochem Francia-Magyar Finomkemiai Kft, based in Hungary, thereby making it a wholly owned subsidiary. The Company hereby announces that the conditions stipulated in the agreement have been fulfilled, and the acquisition has been completed.

1. Completion Date of Acquisition

August 25, 2026.

2. Future Outlook

The impact of this matter on our consolidated financial results for the fiscal year ending March 31, 2027, is currently under close examination. If any matters requiring disclosure arise in the future, such as revisions to our financial forecasts, we will disclose them promptly.

Please refer to the attached document, "Hodogaya Chemical × Framochem: A Full-Scale Launch — Creating New Value in the Global Market by Combining the "DNA of Japan's Pioneer" and "Europe's Leading Technological Capabilities".

Hodogaya Chemical × Framochem: A Full-Scale Launch

Creating New Value in the Global Market by Combining the "DNA of Japan's Pioneer" and "Europe's Leading Technological Capabilities"



Managing Directors

- Watanabe Noriyuki (Executive Officer of Hodogaya Chemical) <4th from right>
- Vörös Tamás (CEO of Framochem) <4th from left>

Following our announcement on March 27, 2026, titled "Notice Regarding Acquisition of Equity Interest (Conversion into a Wholly-Owned Subsidiary) of Framochem Francia-Magyar Finomkémiai Kft (hereinafter 'Framochem')," we are pleased to announce that all acquisition procedures (closing) based on the Quota Purchase Agreement were completed as scheduled on August 25, 2026.

Consequently, Framochem has become our wholly-owned subsidiary (consolidated subsidiary), and from today, under a new management structure, we have launched full-scale business operations that integrate the strengths of both companies.

【Strategic Significance in the New Medium-Term Management Plan "CODE/CHORD 2030"】

We announced our new medium-term management plan, "CODE/CHORD 2030," covering the five-year period from the fiscal year ending March 2027 to the fiscal year ending March 2031, on May 15 of this year. In this plan, the first three years are positioned as the "Three Years of Transformation," with the basic policy of boldly executing discontinuous growth strategies, including M&As, along with structural reforms and portfolio shifts.

This conversion of Framochem into a wholly-owned subsidiary marks the first step of our most important measure (discontinuous growth strategy) to further strengthen the "Specialty Chemicals (Phosgene Derivatives) Business" in the Functional Polymers segment.

The "DNA of Japan's pioneer," stemming from our start as the first company to manufacture phosgene in Japan in 1926, will be fused with the "Europe's leading technological capabilities and customer base" of Framochem, which supplies high-quality active pharmaceutical ingredients (APIs) and intermediates to mega-pharmas and major chemical companies in the European market. Through this, in addition to maintaining and deepening our existing production and export systems from domestic bases, we will establish a "Japan-Europe Dual Hub System" by acquiring a direct manufacturing base in the European demand area. This will solidify our position as a "Global Niche Top" in the worldwide market for phosgene derivatives.

【Comments from the Top Management of Both Companies】

Matsumoto Yuto, Representative Director and President, Hodogaya Chemical Co., Ltd.

I am truly delighted that we have successfully reached the closing and can welcome Framochem to the Hodogaya Chemical Group. More than a decade ago, I personally visited their site twice. Since then, having witnessed their high technological capabilities firsthand, I have felt a strong connection over the years.

This year, our company celebrates its 110th anniversary and the 100th anniversary of Japan's first phosgene production. It is a great pleasure to embark on this journey in such a milestone year together with a company that has built a prominent position in Europe. Going forward, staff in Japan and Europe will unite as one team. Under the new medium-term management plan "CODE/CHORD 2030," we will maximize synergies and further enhance our competitiveness in the global market."

Vörös Tamás, Managing Director and CEO, Framochem

It is both a great honor and a meaningful recognition for Framochem that Hodogaya Chemical Group has acknowledged our company's decades of achievements and expertise through this acquisition. Becoming part of a highly respected group with a 110-year history opens an exciting new chapter for our company.

Since our foundation in 1993, Framochem has built a leading market position through continuous development, technical excellence, and reliability. We believe that long-term success is founded on customer trust, mutual respect, and close cooperation.

Looking ahead, we are particularly excited about the opportunities this partnership creates. By combining Framochem's strong European market presence, manufacturing capabilities, and customer relationships with Hodogaya's century-long expertise and global vision, we can accelerate growth, create new value, and strengthen our position in international markets. We greatly appreciate HCC's trust and look forward to building a successful future together as one team.